6711-46-2

Basic information

• Product Name: N,N-dimethyl-N'-phenylethylenediamine
• Synonyms: N,N-dimethyl-N'-phenylethylenediamine;N,N-Dimethyl-N'-phenyl-1,2-ethanediamine;N,N-Dimethyl-N'-phenylethane-1,2-diamine;1,2-Ethanediamine, N,N-dimethyl-N'-phenyl-;1,2-Ethanediamine, N1,N1-dimethyl-N2-phenyl-;Einecs 229-760-3
• CAS NO: 6711-46-2
• Molecular Formula: C₁₀H₁₆N₂
• Molecular Weight: 164.24744
• EINECS: 229-760-3
• Mol File: 6711-46-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 117-118 °C(Press: 8 Torr)
• Appearance: /
• Density: 0.991±0.06 g/cm3(Predicted)
• PKA: 8.83±0.28(Predicted)
• CAS DataBase Reference: N,N-dimethyl-N'-phenylethylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-dimethyl-N'-phenylethylenediamine(6711-46-2)
• EPA Substance Registry System: N,N-dimethyl-N'-phenylethylenediamine(6711-46-2)

Safety Data

• Hazardous Substances Data: 6711-46-2(Hazardous Substances Data)

Usage

General Description

N,N-dimethyl-N'-phenylethylenediamine, also known as DMEDA, is a chemical compound commonly used as a catalyst in the production of polyurethane foams and epoxy resins. It is also an effective curing agent for certain types of adhesives and sealants. DMEDA is a clear to pale yellow liquid with a strong amine-like odor and is highly soluble in water and common organic solvents. It is classified as a hazardous substance and should be handled with caution due to its potential to cause skin and eye irritation, as well as respiratory and allergic reactions. Additionally, DMEDA may be harmful if ingested or inhaled, and proper protective equipment and handling procedures should be followed to minimize exposure to this chemical.

Upstream product

• 107-99-3 2-(dimethylamino)ethyl chloride 
• 62-53-3 aniline 
• 100-35-6 2-(diethylamino)ethyl chloride 
• 591-50-4 iodobenzene 
• 108-00-9 N,N-dimethylethylenediamine 
• 108-90-7 chlorobenzene 
• 52334-92-6 2-(N,N-dimethylamino)ethoxide 
• 108-86-1 bromobenzene 
• 961-71-7 Antergan 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 

Downstream Products

• 92650-92-5 N-(5-chloro-[2]thienylmethyl)-N',N'-dimethyl-N-phenyl-ethylenediamine 
• 14584-75-9 N'-(4-methoxybenzyl)-N,N-dimethyl-N'-phenylethane-1,2-diamine 
• 36790-23-5 N-(2-methoxy-ethyl)-N',N'-dimethyl-N-phenyl-ethylenediamine 
• 1007346-58-8 N-(4-bromo-3-fluorophenyl)-N',N'-dimethyl-N-phenylethane-1,2-diamine 
• 1426831-89-1 C₁₉H₂₀N₂O 
• 1426831-86-8 C₁₉H₂₀N₂O 
• 859629-78-0 N-[(4-chlorophenyl)methyl]-N-[2-(dimethylamino)ethyl]phenylamine 
• 88099-08-5 N-phenyl-N-(2-dimethylaminoethyl)-5-methyl-3-phenyl-4-isoxazole carboxamide 
• 18184-81-1 2.2'-Dimethoxy-benzilsaeure-N-<β-dimethyl-amino-ethyl>-anilid 
• 18184-86-6 2.2'-Dichlor-benzilsaeure-N-<β-dimethylamino-ethyl>-anilid 

Relevant articles and documents

Design, synthesis and biological activity of a novel ethylenediamine derivatives as H1 receptor antagonists

In this study, a series of novel ethylenediamine compounds were obtained by structural modification of the lead compounds with thonzylamine, and using the principle of modifying by bioisostere formation and modification with alkyl groups. In vitro assay, the biological activities showed that the target compounds have good properties in inhibiting mast cell degranulation and releasing histamine and β-aminohexidase, such as the compounds 5c, 5g, 5k, 5l and 5o, especially of compound 5k to mast cell degranulation is IC50 = 0.0106 ± 0.001 μmol?L?1, histamine release was IC50 = 0.0192 ± 0.005 μmol?L?1 and β-hexosaminidase release was IC50 = 0.0455 ± 0.002 μmol?L?1 in vitro. At the same time, in vivo biological activities assay results showed that have a good Histamie induce bronchospasm effect with relatively long duration and good protective effect in vivo, among which the protective effect of compound 5k was 79.74 ± 0.30%, compounds 5c, 5g, 5k, 5l and 5o could inhibit the capillary permeability of increasing which were caused by histamine.

SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Provided are sulfonylaminopyridine compounds that are inhibitors of ITK kinase, compositions containing these compounds and methods for treating diseases mediated by ITK kinase. In particular, provided are compounds of Formula (I), (II) or (III), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where n, R1, R2, R3, R6 and R7 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by ITK kinase in a patient.

Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction

Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor 3 (VEGFR3) are tyrosine kinases, which function as key modulators of survival and metastasis signals in cancer cells. Previously, we reported that small molecule chlorpyramine hydrochloride (C4) specifically targets the interaction between FAK and VEGFR3 and exhibits anti-tumor efficacy. In this study, we designed and synthesized a series of 1 (C4) analogs on the basis of structure activity relationship and molecular modeling. The resulting new compounds were evaluated for their binding to the FAT domain of FAK and anti-cancer activity. Amongst all tested analogs, compound 29 augmented anti-proliferative activity in multiple cancer cell lines with stronger binding to the FAT domain of FAK and disrupted the FAK-VEGFR3 interaction. In conclusion, we hope that this work will contribute to further studies of more potent and selective FAK-VEGFR3 protein-protein interaction inhibitors.